The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

The world's population is rapidly ageing. For the first time in history, adults over 65 now outnumber children under five. By 2030, nearly 1 billion ...

From flu to gastro and RSV, these are the top five viruses spreading in winter 2025 – and what doctors recommend to help you ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Federal health officials issued new guidance last week on who should have the COVID-19 vaccine, and it no longer includes ...

Experts say new immunisation program working, but some babies missing outThe number of Australian babies admitted to hospital ...

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 ...

Moderna has announced FDA approval for its new COVID-19 vaccine, mNexspike (mRNA-1283). This next-generation shot targets a ...

Patients with RSV hospitalization have increased odds of any acute cardiovascular event compared with COVID-19 hospitalizations.